Target Audience and Goal Statement

This educational activity is intended for an audience of oncologists, gastroenterologists, surgeons, and other clinicians on the multidisciplinary team in the United States.

The goal of this activity is for learners to be better able to incorporate immunotherapy strategies into the management of patients with HCC.

Upon completion of this activity, participants will:

• Have increased knowledge regarding the clinical trial data associated with immunotherapy-based strategies for frontline treatment of advanced unresectable HCC.
• Have greater competence related to selecting the most appropriate immunotherapy-based strategies for first-line treatment of advanced unresectable HCC.
• Demonstrate greater confidence in their ability to differentiate the benefits of immunotherapy-based combination regimens for first-line treatment of advanced unresectable HCC.

Available Beginning: December 13, 2024

Approximate Time to Complete: 30 minutes

CE Credits: 0.50 AMA PRA Category 1 Credit™/ABIM MOC points; available through 12/13/2025, 11:59 PM EST

Developed through a partnership between SITC and Medscape.

Access Course

This article is for people who have advanced kidney cancer and their caregivers, or anyone who wants to learn more about advanced kidney cancer. The goal of this activity is to help people engage in shared decision-making with their doctor about treatment.

In this course, you will learn about:

• What advanced kidney cancer is
• Making a treatment plan with your doctor
• Treatment options for advanced kidney cancer
• Possible side effects of treatment
• Questions to ask your doctor

Available beginning: February 24, 2022

Approximate Time to Complete: 30 minutes

Developed through a partnership between SITC and Medscape.

Access Course

Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.

This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.

The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.

Approximate Time to Complete: 30 minutes

Credit Available: Apr. 30, 2019- Apr. 30, 2020

Developed through a partnership between SITC and Medscape.

Access Course

Nursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.

This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.

The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.

Approximate Time to Complete: 30 minutes

Credit Available: Apr. 30, 2019 - Apr. 30, 2020

Developed through a partnership between SITC and Medscape.

Access Course

This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

You will learn about:

• What chemotherapy is and how it is used to treat advanced bladder cancer
• What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
• The potential side effects of chemotherapy and checkpoint inhibitors
• Why the side effects from chemotherapy and checkpoint inhibitors are different
• Questions to ask your doctor

Available beginning: April 26, 2019

Approximate Time to Complete: 30 minutes

Developed through a partnership between SITC and Medscape.

Access Course

Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.

This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.

Credit Available: Feb. 25, 2019 - Feb. 25, 2020

Approximate Time to Complete: 75 minutes

Developed through a partnership between SITC and Medscape.